Top Abstract Purchase Related
Home
>
Node
>
Subnode

Current status and future direction of postoperative adjuvant therapy in breast cancer

Osaki, A.; Saeki, T.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(9): 1406-1411

2011

ISSN/ISBN: 0385-0684
PMID: 21918336
Document Number: 655546
The Panel of the St. Gallen 2011 consensus meeting considered the major breast cancer subtypes classified by the expression of hormone receptors and HER2, and the Ki67-labelling index was substituted for microarray-based intrinsic subtypes. When choosing a treatment strategy for breast cancer, the biological property of the tumor itself is given greater importance than the anatomical spreading in the hosts recently. The treatment strategy of adjuvant therapies for breast cancer will be decided according to these simplified intrinsic subtypes: luminal A, luminal B, HER2 positive, and triple negative. The biological markers and targeted therapies will contribute to the advancement of personalized medicine.

Document emailed within 1 workday
Secure & encrypted payments

Osaki, A.; Saeki, T. 2007: Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus Nihon Rinsho. Japanese Journal of Clinical Medicine 65 Suppl. 6: 407-413
Wolff, A.C. 2005: Current status of taxanes as adjuvant therapy for early-stage breast cancer International Journal of Fertility and Women's Medicine 50(5 Pt 1): 227-229
Messadi, D.V.; Sato, K. 2016: Oral Cancer Chernoprevention: Current Status and Future Direction Journal of the California Dental Association 44(2): 101-111
Sonoo, H. 2007: Current status and future prospects for breast cancer therapy Nihon Rinsho. Japanese Journal of Clinical Medicine 65 Suppl. 6: 391-395
Yamaguchi, M.; Fukuyama, Y.; Ichinose, Y. 2003: Current status of the neo-adjuvant and adjuvant therapy for the resectable non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(2): 203-208
Kodaira, S. 1997: The current status of postoperative adjuvant chemotherapy for colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(10): 1230-1238
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Tokuda, Y. 2014: The Japanese Breast Cancer Society Breast Cancer Registry in the National Clinical Database: current status and future perspectives Nihon Geka Gakkai zasshi 115(1): 17-21
Abe, R.; Tsuchiya, A.; Koie, H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Motoki, R. 1988: Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(9): 2707-2712
Senn, H.J. 1987: Current status of adjuvant chemo- and hormone therapy in resectable breast carcinoma Schweizerische Rundschau für Medizin Praxis 76(43): 1193-1199
Kurebayashi, J. 2006: Postoperative adjuvant therapy for premenopausal patients with breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 64(10): 1963-1969
O'Connell, M.J. 2004: Current status of adjuvant therapy for colorectal cancer Oncology 18(6): 751
Kato, A.; Miyazaki, M. 2014: Current status of adjuvant therapy for biliary tract cancer Nihon Geka Gakkai Zasshi 115(4): 206-211
Hudis, C.A. 1999: The current state of adjuvant therapy for breast cancer: focus on paclitaxel Seminars in Oncology 26(1 Suppl 2: 1-5
Berndt, H.; Eichhorn, J.H.; Widow, W. 1980: A controlled clinical trial on adjuvant therapy by preoperative irradiation or postoperative cyclophosphamide in breast cancer Archiv für Geschwulstforschung 50(5): 468-479
Grem, J.L.; Hoth, D.F.; Hamilton, J.M.; King, S.A.; Leyland-Jones, B. 1987: Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid Cancer Treatment Reports 71(12): 1249-1264
Yoshida, M.; Saji, S.; Takagi, H.; Takeuchi, S.; Tsuda, H.; Nimura, Y.; Mizumoto, R.; Miyazaki, I.; Kobayashi, S.; Noguchi, M. 1993: A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. the Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(15): 2325-2333
Hirai, F. 2015: III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 940-943
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176